Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1Dermatologic 1

Conditions

Melanoma 105Skin Neoplasms 17Neoplasm Metastasis 15Neoplasms 10Uveal Melanoma 9Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Lung Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Lymphoma 2Eye Neoplasms 2Carcinoma, Hepatocellular 2Urogenital Neoplasms 1Turcot syndrome 1Sezary Syndrome 1Sarcoma, Synovial 1

Interventions

Radiosurgery 22Ipilimumab 17Nivolumab 16pembrolizumab 11Temozolomide 9encorafenib 8dabrafenib 8binimetinib 8Magnetic Resonance Spectroscopy 6trametinib 5Bevacizumab 5CTLA-4 Antigen 4cobimetinib 3Thalidomide 3Radiotherapy 3Paclitaxel 3entrectinib 2cediranib 2Vemurafenib 2Spermine Synthase 2Specimen Handling 2Radiation 2Pemetrexed 2Opdualag 2Drug Therapy 2Carboplatin 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 214-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2130-nm albumin-bound paclitaxel 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Interleukin-2 × Dermatologic × Clear all
NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡